Anti-CD19 Recombinant Immunotoxin DT-AntiCD19 (DT390-FMC63(scFv)) (CAT#: BioBet-IT009Z) Datasheet

Target
CD19
IT Type
Antibody-based IT
Description
The anti‐human CD19 immunotoxins was constructed using DT390 and the codon‐optimized scFv (FMC63) nucleotide sequences. DT390 and scFv (FMC63) are connected by a G4S (four glycines and one serine residue) linker. Six histidines (6x His tag) were added to the C terminus of each construct to facilitate protein purification.
Indication
Refractory B-cell malignancies; B-cell Leukemia/Lymphoma
Classification
Immuntoxin; biobetter
Construction
DT390-FMC63(scFv)

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 Molecule
Background
CD19 (CD19 Molecule) is a Protein Coding gene.Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency. Among its related pathways are RET signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. Gene Ontology (GO) annotations related to this gene include signal transducer activity, downstream of receptor.
Alternative Names
CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4;
Gene ID
Entrez Gene: 930
UniProt ID
UniProtKB: P15391
Antibody Clone
FMC63
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Type
scFv
Host
Mouse
Species Reactivity
Human
Antibody Description
Based on comparative studies, antigen recognition and positive reaction with CD19 transfected cell lines, the specificity of this antibody is the same as that of CD19 monoclonal antibody (Zola et al., 1988, 1989). It can detect 96 kD single chain glycoproteins on the surface of human B lineage cells (including pre-B cells). B cells can be detected in peripheral blood and tissues. The antibody can react with most B-cell malignancies, including chronic lymphocytic leukemia and most lymphomas, but does not include multiple myeloma.

Cellular reactivity:
Normal: Stain all B lymphocytes in peripheral blood and spleen. It is negative for granulocytes, monocytes, platelets, red blood cells and T lymphocytes.

clinical:
B-cell chronic lymphocytic leukemia (B-CLL) +
Lymphocytic leukemia (PLL) +
Hairy cell leukemia (HCL) +
Common acute lymphocytic leukemia (CALL) +
Acute lymphocytic leukemia before B (before B-ALL) +
NULL Acute Lymphocytic Leukemia (NULL-ALL) +
Common T-lymphocytic leukemia (T-CLL)-
Antibody Indication
Refractory B-cell malignancies; B-cell Leukemia/Lymphoma
Toxic Moiety
DT390
Organism
Corynebacterium
Family
Diphtheria toxin
Molecular Mass
35.64kD
Toxic MOA
Diphtheria toxin (DT) is one of the most extensively studied bacterial toxins with intracellular action. The first 390 amino acid residues of DT (DT390) contain the catalytic domain or A chain of DT that inhibits protein synthesis by ADP ribosylation of elongation factor 2 (EF-2) and the translocation domain that translocates the catalytic domain to the cytosol by interaction with cytosolic Hsp90 and thioredoxin reductase.

The antibody portion mediated selective binding to target cells, while the toxin portion mediated translocation into the cytosol and subsequent cell killing.

Refractory B-cell malignancies; B-cell Leukemia/Lymphoma

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK